• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOMET FRANCE S.A.R.L. REFOBACIN BONE CEMENT R 1X40-3; BONE CEMENT, ANTIBIOTICS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOMET FRANCE S.A.R.L. REFOBACIN BONE CEMENT R 1X40-3; BONE CEMENT, ANTIBIOTICS Back to Search Results
Catalog Number 3003940001-3
Device Problem Unsealed Device Packaging (1444)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Date 09/23/2020
Event Type  malfunction  
Manufacturer Narrative
(b)(4).Foreign report source: (b)(6).The device was not returned to the manufacturer yet.Therefore, it could not be analyzed yet.The device manufacturing quality record indicates that the released product met all requirements to perform as intended.The investigation is pending.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.Zimmer biomet will continue to monitor for trends.
 
Event Description
It has been that during the initial surgery two sterile packs of the cement of polymer powder have leaked.No adverse events have been reported as a result of the malfunction.
 
Event Description
It has been reported that during operation, the cement powder packet was found not sealed properly, and the powder has leaked inside the packaging.No adverse events have been reported as a result of the malfunction.
 
Manufacturer Narrative
(b)(4).This follow-up report is being submitted to relay additional information.The two products involved in the complaint have been received.The product analysis shows that on the two inner pouches, the right sealing is opened on 3/6 of the length.The reported event is confirmed.The device manufacturing quality record indicates that the released product met all requirements to perform as intended.Eight complaints have been recorded on refobacin bone cement r 1x40-3, reference 3003940001-3, over the batch a925ca2503.According to available data, the most probable root cause is due to packaging issue (sealing process).Corrective action has been initiated to address reported issue.A customer letter will be send regarding the reported issue.If any further information is found which would change or alter any conclusions or information, a supplemental will be filed accordingly.Zimmer biomet will continue to monitor for trends.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
REFOBACIN BONE CEMENT R 1X40-3
Type of Device
BONE CEMENT, ANTIBIOTICS
Manufacturer (Section D)
BIOMET FRANCE S.A.R.L.
plateau de lautagne bp75
valence cedex 26903
FR  26903
MDR Report Key10703205
MDR Text Key220941576
Report Number3006946279-2020-00206
Device Sequence Number1
Product Code MBB
Combination Product (y/n)N
PMA/PMN Number
N/A
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup
Report Date 11/19/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/20/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date05/31/2022
Device Catalogue Number3003940001-3
Device Lot NumberA925CA2503
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/10/2020
Was the Report Sent to FDA? No
Date Manufacturer Received11/10/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-